Voyager Therapeutics
VYGR
107 hedge funds and large institutions have $230M invested in Voyager Therapeutics in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 23 closing their positions.
93% more call options, than puts
Call options by funds: $386K | Put options by funds: $200K
9% more capital invested
Capital invested by funds: $211M → $230M (+$18.4M)
7% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 30
0.22% less ownership
Funds ownership: 62.03% → 61.81% (-0.22%)
3% less funds holding
Funds holding: 110 → 107 (-3)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$3.2M |
| 2 |
Morgan Stanley
New York
|
+$1.4M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.31M |
| 4 |
AACP
Advantage Alpha Capital Partners
San Francisco,
California
|
+$1.28M |
| 5 |
BlackRock
New York
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$2.85M |
| 2 |
Renaissance Technologies
New York
|
-$1.6M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.6M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.54M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.23M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Simplex Trading
Chicago,
Illinois
| – | -$54.9K | -7,572 | Closed |
|
|
GCM
127
Gladius Capital Management
Chicago,
Illinois
| – | -$24.7K | -3,182 | Closed |
|
|
CA
128
Clearstead Advisors
Cleveland,
Ohio
| – | -$388 | -50 | Closed |
|
|
PA
129
Parallel Advisors
San Francisco,
California
| – | -$380 | -49 | Closed |
|
|
OIA
130
Optimum Investment Advisors
Chicago,
Illinois
| – | -$333 | -43 | Closed |
|
VYGR Hedge Fund Activity: Q4 2023 in Review
107 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2023, worth a combined $230M — up 8.7% from $211M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VYGR and 20 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 32 added.
The largest buyer was AQR Capital Management, adding an estimated $3.2M. The largest seller was Hillsdale Investment Management, exiting entirely with an estimated $2.85M sold.
- 107 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2023, down from 110 in Q3 2023.
- Funds reported $230M of Voyager Therapeutics stock for Q4 2023, up 8.7% quarter-over-quarter.
- 20 funds opened new Voyager Therapeutics positions in Q4 2023 and 23 closed out, a net change of -3 holders.
- The largest Voyager Therapeutics buyer in Q4 2023 was AQR Capital Management, an estimated $3.2M added.
- The largest Voyager Therapeutics seller in Q4 2023 was Hillsdale Investment Management, an estimated $2.85M sold.
Based on aggregated 13F filings for Q4 2023.